Displaying 1 - 29 of 29 tests
NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile

The NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile is performed by the sequencing of select exons in the genes BCL1 (CCND1), IDH1, IDH2, DNMT3A, TET2 and RHOA

Molecular
NeoTYPE AML Favorable-Risk Profile

This test is performed by sequencing of select exons of the genes FLT3 and KIT. Test orders include summary interpretation of all results together. Individual genes from a validated list of myeloid genes can be added-on.

Molecular
NeoTYPE Liposarcoma Fusion Profile

The NeoTYPE Liposarcoma Fusion Profile combines next-generation sequencing to detect translocations in the genes EWSR1, FUS, HMGA2, and PLAG1 with FISH testing for MDM2 to detect amplifications relevant in liposarcoma. FISH components of NeoTYPE Profiles may be ordered as “Tech-Only” by pathology clients who wish to perform the professional component.

Molecular
NeoTYPE® AML Prognostic Profile

This test is performed by sequencing the entire coding regions of the genes listed. ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 including V617F and Exons 12+14, KIT, KMT2A (MLL), KRAS, NPM1, NRAS, PDGFRA, PHF6, PTPN11, RUNX1, SETBP1, STAG2, TET2, TP53 and WT1. FLT3 is performed by multiple methods. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together. The AML Prognostic Profile may also be ordered as reflex after intermediate cytogenetics in the AML Reflex Panel (see separate AML Reflex Panel listing). For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, we recommend instead the NeoTYPE MDS/CMML Profile.

Molecular
NeoTYPE® Brain Tumor Profile

The NeoTYPE Brain Tumor Profile analyzes 49 biomarkers through a combination of next-generation sequencing (NGS), other molecular methods, FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions.

  • NGS (39 genes + 2 biomarkers): AKT1, ATRX, BRAF, CDK6, CDKN2A, CIC, CTNNB1, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, FUBP1, H3F3A, HIST1H3C, HRAS, IDH1, IDH2, KRAS, MET, Microsatellite Instability (MSI), MYC, MYCN, NF1, NF2, NRAS, NTRK1 fusions, NTRK2 fusions, NTRK3 fusions, PIK3CA, PTCH1, PTEN, RB1, SETD2, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
  • Other Molecular (2 genes): EGFRvIII Analysis, MGMT Promoter Methylation Analysis
  • FISH (6 FISH): 1p/19q Deletion, BRAF, MET, MYCN, PDGFRA, PTEN (tech-only available)
  • IHC (1 biomarker): PD-L1 22C3 (tech-only available)
Molecular
NeoTYPE® Breast Tumor Profile

The NeoTYPE Breast Tumor Profile analyzes 30 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (24 genes + 2 biomarkers): AKT1, BRAF, BRCA1, BRCA2, CTNNB1, EGFR, ESR1, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), NRAS, PIK3CA, PTEN, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
  • FISH (2 FISH): MET, PTEN (tech-only available)
  • IHC (2 biomarkers): PD-L1 SP142, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® Cervical Tumor Profile

The NeoTYPE Cervical Tumor Profile analyzes 28 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (22 genes + 2 biomarkers): AKT1, BRAF, CTNNB1, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, HRAS, KRAS, MET, Microsatellite Instability (MSI), NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
  • FISH (2 FISH): MET, PTEN (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® CLL Prognostic Profile

This test is performed by sequencing the entire coding regions of the genes ATM, BIRC3, BTK, CARD11, CD79B, CXCR4, MYD88, NOTCH1, SF3B1, TP53, plus IgVH Mutation Analysis and the CLL FISH Panel as noted. Test orders include summary interpretation of all results together. Individual genes from a validated list of genes can be added-on. Test orders include summary interpretation of all results together. FISH components of NeoTYPE Profiles may be ordered as "Tech-Only" by pathology clients who wish to perform the professional component.

Molecular
NeoTYPE® Colorectal Tumor Profile

The NeoTYPE  Colorectal Tumor Profile analyzes 31 biomarkers through a combination of next-generation sequencing (NGS), other molecular methods, FISH, and IHC as listed below.  Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (23 genes + 2 biomarkers): AKT1, APC, BRAF, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), MLH1, NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
  • Other Molecular (1 biomarker): MLH1 Promoter Methylation
  • FISH (3 FISH): MET, PTEN, RET (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® Discovery Profile for Solid Tumors

The NeoTYPE Discovery Profile analyzes 336 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • FISH (9 FISH): ALK, BRAF, HER2, MET, MYC, PDGFRA amplifications, PTEN, RET, ROS1 (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
  • NGS (323 genes + 2 biomarkers): ABL1, ABL2, ACVR1B, AKT1, AKT2, AKT3, ALK, AMER1, APC, AR, ARAF, ARFRP1, ARID1A, ARID1B, ARID2, ASXL1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORL1, BLM, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTK, C11orf30, CARD11, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CHD2, CHD4, CHEK1, CHEK2, CIC, CREBBP, CRKL, CRLF2, CSF1R, CTCF, CTNNA1, CTNNB1, CUL3, CXCR4, CYLD, DAXX, DDR2, DICER1, DNMT3A, DOT1L, EGFR, EP300, EPCAM, EPHA3, EPHA5, EPHA7, EPHB1, ERBB2, ERBB3, ERBB4, ERG, ERRFI1, ESR1, EZH2, FAM46C, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FAS, FAT1, FBXW7, FGF10, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLT1, FLT3, FLT4, FOXL2, FOXP1, FRS2, FUBP1, GABRA6, GATA1, GATA2, GATA3, GATA4, GATA6, GID4, GLI1, GNA11, GNA13, GNAQ, GNAS, GPR124, GRIN2A, GRM3, GSK3B, H3F3A, HGF, HIST1H3C, HNF1A, HRAS, HSD3B1, HSP90AA1, IDH1, IDH2, IGF1R, IGF2, IKBKE, IKZF1, IL7R, INHBA, INPP4B, IRF2, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, KAT6A, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIT, KLHL6, KMT2A, KMT2C, KMT2D, KRAS, LMO1, LRP1B, LYN, LZTR1, MAGI2, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1, MET, Microsatellite Instability (MSI), MITF, MLH1, MPL, MRE11A, MSH2, MSH6, MTOR, MUTYH, MYC, MYCL, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NSD1, NTRK1, NTRK2, NTRK3, NUP93, PAK3, PALB2, PARK2, PAX5, PBRM1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PIK3C2B, PIK3CA, PIK3CB, PIK3CG, PIK3R1, PIK3R2, PLCG2, PMS2, POLD1, POLE, PPP2R1A, PRDM1, PREX2, PRKAR1A, PRKCI, PRKDC, PRSS8, PTCH1, PTEN, PTPN11, QKI, RAC1, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L, RAF1, RANBP2, RARA, RB1, RBM10, RET, RICTOR, RNF43, ROS1, RPTOR, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SETD2, SF3B1, SLIT2, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMO, SNCAIP, SOCS1, SOX10, SOX2, SOX9, SPEN, SPOP, SPTA1, SRC, STAG2, STAT3, STAT4, STK11, SUFU, SYK, TAF1, TBX3, TERC, TERT promoter and coding sequence, TET2, TGFBR2, TNFAIP3, TNFRSF14, TOP1, TOP2A, TP53, TSC1, TSC2, TSHR, U2AF1, VEGFA, VHL, WISP3, WT1, XPO1, ZBTB2, ZNF217, ZNF703, Tumor Mutation Burden (TMB)
Molecular
NeoTYPE® Endometrial Tumor Profile

The NeoTYPE Endometrial Tumor Profile analyzes 28 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (22 genes + 2 biomarkers): AKT1, BRAF, EGFR, ESR1, FGFR1, FGFR2, FGFR3, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), NRAS, PDGFRA, PIK3CA, POLE, PTEN, PTPN11, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
  • FISH (2 FISH): MET, PTEN (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® Esophageal Tumor Profile

The NeoTYPE Esophageal Tumor Profile analyzes 28 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (22 genes + 2 biomarkers): AKT1, BRAF, CTNNB1, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
  • FISH (2 FISH): MET, PTEN (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® Gastric Tumor Profile

The NeoTYPE Gastric Tumor Profile analyzes 28 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (22 genes + 2 biomarkers): AKT1, BRAF, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
  • FISH (2 FISH): MET, PTEN (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® GI Predictive Profile

The NeoTYPE GI Predictive Profile analyzes 10 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (5 genes + 2 biomarkers): BRAF, HRAS, KRAS, Microsatellite Instability (MSI), NRAS, TERT Promoter, Tumor Mutation Burden (TMB)
  • FISH (1 FISH): HER2 (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® GIST and Soft Tissue Tumor Profile

The NeoTYPE GIST/Soft Tissue Tumor Profile analyzes 41 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions.

  • NGS (36 genes + 2 biomarkers): AKT1, AKT2, AKT3, ATM, BRAF, CDKN2A, CTNNB1, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, GNAS, HRAS, KIT, KRAS, MAP2K1, MET, Microsatellite Instability (MSI), NF1, NRAS, NTRK1 fusions, NTRK2 fusions, NTRK3 fusions, PDGFRA, PIK3CA, PTEN, PTPN11, SDHA, SDHB, SDHC, SDHD, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
  • FISH (2 FISH): MET, PTEN (tech-only available)
  • IHC (1 biomarker): PD-L1 22C3 (tech-only available)
Molecular
NeoTYPE® Head & Neck Tumor Profile

The NeoTYPE Head & Neck Tumor Profile analyzes 32 biomarkers through a combination of next-generation sequencing (NGS), other molecular methods, FISH, and IHC as listed below. Test orders include summary interpretation of all results that help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (25 genes + 2 biomarkers): AKT1, ATM, BRAF, CDKN2A, CTNNB1, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, HRAS, IDH1, IDH2, KRAS, MET, Microsatellite Instability (MSI), NOTCH1, NRAS, PIK3CA, PTEN, RB1, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
  • Other Molecular (1 biomarker): HPV DNA
  • FISH (3 FISH): MET, PTEN, RET (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® JMML Profile

This test is performed by sequencing the entire coding regions of the genes listed. BRAF, CBL, CEBPA, FLT3, HRAS, JAK2 including V617F and Exons 12+14, JAK3, KIT, KRAS, NPM1, NRAS, PDGFRA, PTEN, PTPN11, and SETBP1. FLT3 is performed by multiple methods. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together.

Molecular
NeoTYPE® Liver/Biliary Tumor Profile

The NeoTYPE Liver/Biliary Tumor Profile analyzes 31 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (25 genes + 2 biomarkers): AKT1, ATM, BRAF, CDKN2A, CTNNB1, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, HRAS, IDH1, IDH2, KRAS, MET, Microsatellite Instability (MSI), NOTCH1, NRAS, PIK3CA, PTEN, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
  • FISH (2 ISH): MET, PTEN (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® Lung Tumor Profile

The NeoTYPE Lung Tumor Profile analyzes 32 biomarkers through a combination of next-generation sequencing (NGS), other molecular methods, FISH, and IHC as listed below.  Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (21 genes + 2 biomarkers): AKT1, BRAF, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, KIT, KRAS, MET, Microsatellite Instability (MSI), NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
  • Other Molecular (1 biomarker): MET Exon 14 Deletion Analysis
  • FISH (6 FISH): ALK, HER2, MET, PTEN, RET, ROS1 (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® Lymphoma Profile

This test is performed by multiple methods to detect mutations in the following genes BCL1, BCL2, BCL6, BRAF, CARD11, CD79B, EZH2, MYD88, NOTCH1, NOTCH2, NRAS and TP53. The test is performed by sequencing the entire coding regions of the genes listed unless otherwise noted. BCL1/ IgH translocation t(11;14) is performed by real-time PCR and BCL2 t(14;18) is performed by fragment length analysis. Test orders include summary interpretation of all results together.

Molecular
NeoTYPE® MDS/CMML Profile

This test is performed by sequencing the entire coding regions of the genes listed unless another method is noted. ASXL1, BCOR, BCORL1, BRAF, CBL, CEBPA, CUX1, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 including V617F and Exons 12+14, KIT, KRAS, NF1, NPM1, NRAS, PDGFRA, PPM1D, PTEN, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, and ZRSR2. FLT3 is performed by multiple methods. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together.

Molecular
NeoTYPE® Melanoma Profile

The NeoTYPE Melanoma Profile assesses the most commonly-mutated driver mutations in primary or metastatic melanoma to determine prognosis and identify established and clinical trial-based therapeutic options. This NeoTYPE Profile is for histologically-confirmed melanoma and is not appropriate for differentiating melanoma from ambiguous melanocytic lesions. For that indication, please see the separate listing for the NeoSITE™ Melanoma FISH Panel.

  • NGS (18 genes + 2 biomarkers): AKT1, BRAF, CTNNB1, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, KIT, Microsatellite Instability (MSI), NRAS, PDGFRA, PTEN, SMO, SRC, TERT Promoter, Tumor Mutation Burden (TMB)
  • FISH (1 FISH): PTEN (tech-only available)
  • IHC (2 biomarkers): PD-L1 28-8, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® MPN Profile

This test is performed by sequencing the entire coding regions of the genes listed unless another method is noted. ABL1, ASXL1, BRAF, CALR, CEBPA, CSF3R, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 including V617F and Exons 12+14, KIT, KRAS, MPL, NF1, NPM1, NRAS, PPM1D, PDGFRA, PTEN, PTPN11, SETBP1, SF3B1, SRSF2, TET2, TP53 and U2AF1. CALR and FLT3 are performed by multiple methods. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together.

Molecular
NeoTYPE® Myeloid Disorders Profile

This test is performed by the sequencing the entire coding regions of the genes listed. ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2 including V617F and Exons 12+14, JAK3, KDM6A, KIT, KRAS, MLL, MPL, MYD88, NF1, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PPM1D, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2. CALR and FLT3 are performed by multiple methods. Test orders include summary interpretation of all results together.

Molecular
NeoTYPE® Other Solid Tumor Profile

The NeoTYPE Other Solid Tumor Profile analyzes 30 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (24 genes + 2 biomarkers): AKT1, BRAF, EGFR, FGFR1, FGFR2, FGFR3, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MET, Microsatellite Instability (MSI), NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, SMAD4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
  • FISH (2 FISH): MET, PTEN (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® Ovarian Tumor Profile

The NeoTYPE Ovarian Tumor Profile analyzes 46 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (36 genes + 2 biomarkers): AKT1, ARID1A, ATM, ATR, BRAF, BRCA1, BRCA2, CDK12, CDKN2A, CDKN2B, CTNNB1, EGFR, ERBB2, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), NF1, NRAS, PIK3CA, POLE, PTEN, RAD51B, RAD51C, RB1, SMAD4, SMO, SRC, STK11, TERT Promoter, TP53, Tumor Mutation Burden (TMB)
  • FISH (6 FISH): EGFR Amplification, HER2, MET, MYC, PTEN, RET (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® Pancreas Tumor Profile

The NeoTYPE Pancreas Tumor Profile analyzes 32 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (25 genes + 2 biomarkers): ARID1A, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), NOTCH1, NRAS, PALB2, PIK3CA, PTEN, SMAD4, SMO, TERT Promoter, TP53, Tumor Mutation Burden (TMB), VHL
  • FISH (3 FISH): HER2, MET, PTEN (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® Precision Profile for Solid Tumors

The NeoTYPE Precision Profile analyzes 50 biomarkers through a combination of next-generation sequencing (NGS) and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (46 genes + 2 biomarkers): AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, ESR1, FBXW7, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, KDR, KIT, KRAS, MET, Microsatellite Instability (MSI), MLH1, NOTCH1, NRAS, PALB2, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TERT Promoter, TP53, Tumor Mutation Burden (TMB), VHL
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular
NeoTYPE® Thyroid Profile

The NeoTYPE Thyroid Tumor Profile analyzes 22 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, NTRK NGS Fusion Profile for NTRK1 fusions, NTRK2 fusions, and NTRK3 fusions will be added by reflex.

  • NGS (16 genes + 2 biomarkers): AKT1, ALK, BRAF, CTNNB1, ERBB2, ERBB4, HRAS, KRAS, MET, Microsatellite Instability (MSI), NRAS, PIK3CA, RET, SMAD4, SMO, SRC, TERT Promoter, Tumor Mutation Burden (TMB)
  • FISH (2 FISH): MET, RET (tech-only available)
  • IHC (2 biomarkers): PD-L1 22C3, Pan-TRK (tech-only available for PD-L1)
Molecular